Form 4: Entrada Therapeutics' Chief Scientific Officer Sells Shares to Cover Tax Obligations

Natarajan Sethuraman, Chief Scientific Officer of Entrada Therapeutics, sold shares of common stock between September 3rd and September 5th, 2024, to cover tax obligations arising from the vesting of restricted stock units.

Summary

• Natarajan Sethuraman, the Chief Scientific Officer of Entrada Therapeutics, Inc., reported the sale of common stock to cover tax obligations.
• The transactions occurred between September 3rd and September 5th, 2024.
• The sales were executed automatically by the company to cover minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units.
• The reporting person sold 469 shares on September 3rd at a weighted average price of $15.7611.
• An additional 151 shares were sold on September 3rd at a weighted average price of $16.9255.
• Another 14 shares were sold on September 3rd at a weighted average price of $17.702.
• On September 4th, 955 shares were sold at a weighted average price of $15.4234.
• Finally, on September 5th, 167 shares were sold at a weighted average price of $15.126.
• Following these transactions, Sethuraman directly owns 187,058 shares of Entrada Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing is a routine disclosure of stock sales to cover tax obligations, which is a common practice. There is no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. This filing indicates that a company insider has sold shares, which can sometimes be interpreted negatively by the market, but in this case, it is explicitly stated that the sale was to cover tax obligations.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but it is unlikely to be significant given the stated reason for the sale.

Key Dates